IL105741A0 - Pharmaceutical compositions for treating cellular hyperproliferation using interleukin-1 inhibitory compounds - Google Patents

Pharmaceutical compositions for treating cellular hyperproliferation using interleukin-1 inhibitory compounds

Info

Publication number
IL105741A0
IL105741A0 IL105741A IL10574193A IL105741A0 IL 105741 A0 IL105741 A0 IL 105741A0 IL 105741 A IL105741 A IL 105741A IL 10574193 A IL10574193 A IL 10574193A IL 105741 A0 IL105741 A0 IL 105741A0
Authority
IL
Israel
Prior art keywords
interleukin
pharmaceutical compositions
inhibitory compounds
cellular hyperproliferation
treating cellular
Prior art date
Application number
IL105741A
Other languages
English (en)
Original Assignee
Genta Inc
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Inc, Univ Michigan filed Critical Genta Inc
Publication of IL105741A0 publication Critical patent/IL105741A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/12Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/15Nucleic acids forming more than 2 strands, e.g. TFOs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/312Phosphonates
    • C12N2310/3125Methylphosphonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IL105741A 1992-05-22 1993-05-19 Pharmaceutical compositions for treating cellular hyperproliferation using interleukin-1 inhibitory compounds IL105741A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88773492A 1992-05-22 1992-05-22

Publications (1)

Publication Number Publication Date
IL105741A0 true IL105741A0 (en) 1993-09-22

Family

ID=25391751

Family Applications (1)

Application Number Title Priority Date Filing Date
IL105741A IL105741A0 (en) 1992-05-22 1993-05-19 Pharmaceutical compositions for treating cellular hyperproliferation using interleukin-1 inhibitory compounds

Country Status (9)

Country Link
EP (1) EP0644765A4 (es)
JP (1) JPH07508977A (es)
KR (1) KR950701528A (es)
AU (1) AU4388993A (es)
CA (1) CA2136349A1 (es)
IL (1) IL105741A0 (es)
MX (1) MX9302951A (es)
NZ (1) NZ253509A (es)
WO (1) WO1993024134A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
ATE428785T1 (de) 1996-03-01 2009-05-15 Euroscreen Sa Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL133913A0 (en) * 1997-07-10 2001-04-30 Therakos Inc Treatment of inflammatory disorders of the bowel and urinary bladder
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO2006084145A2 (en) * 2005-02-02 2006-08-10 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to reduce c-reactive protein
GB0607189D0 (en) * 2006-04-10 2006-05-17 Polybiomed Ltd interleukin IL 1ra composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0353290A4 (en) * 1988-01-21 1990-09-05 Chemex Pharmaceuticals, Inc. Selective inhibition of gene expression by photoactivatable oligonucleotides
EP0527790A4 (en) * 1990-04-09 1993-09-15 The American National Red Cross Rejuvenation compositions and methods for their use
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
IL101978A0 (en) * 1991-05-31 1992-12-30 Genta Inc Neutral oligomers capable of being delivered transdermally and across mucous membranes
HU220098B (hu) * 1991-08-30 2001-10-28 Vertex Pharmaceuticals Incorporated Interleukin-1 béta proteáz enzim, és interleukin-1 béta proteáz inhibitorok

Also Published As

Publication number Publication date
EP0644765A4 (en) 1997-02-26
AU4388993A (en) 1993-12-30
MX9302951A (es) 1994-07-29
KR950701528A (ko) 1995-04-28
EP0644765A1 (en) 1995-03-29
WO1993024134A1 (en) 1993-12-09
NZ253509A (en) 1999-09-29
JPH07508977A (ja) 1995-10-05
CA2136349A1 (en) 1993-12-09

Similar Documents

Publication Publication Date Title
IL117237A0 (en) Pharmaceutical composition for piperidinoalkanol compounds
PH30215A (en) Pharmaceutical compounds
GB9319500D0 (en) Pharmaceutical composition
ZA952046B (en) Benzimidazoles pharmaceutical compositions containing these compounds and processes for preparing them
IL105741A0 (en) Pharmaceutical compositions for treating cellular hyperproliferation using interleukin-1 inhibitory compounds
HU9303261D0 (en) Pharmaceutical compounds
GB2272375B (en) Pharmaceutical composition
ZA93529B (en) Benzimidazoles pharmaceutical compositions containing these compounds and processes for preparing them
ZA931944B (en) Pharmaceutical compounds
ZA911804B (en) 1-azabicyclic compounds,processes and pharmaceutical compositions containing them
IL108197A0 (en) Pharmaceutical composition for preventing or treating arterioscleriosis
GB9221707D0 (en) Pharmaceutical composition
IL106763A0 (en) Pharmaceutical compositions for treating cancer
IL109758A0 (en) Pharmaceutical compositions for treating ulcer
GB9224169D0 (en) Pharmaceutical compounds
GB9226724D0 (en) Pharmaceutical compounds
IL106939A0 (en) Pharmaceutical compositions for treating viral infections
ZA93420B (en) Benzimidazoles pharmaceutical compositions containing these compounds and processes for preparing them
ZA932521B (en) Benzimidazoles pharmaceutical compositions containing these compounds and processes for preparing them
ZA937365B (en) Benzimidazoles pharmaceutical compositions containing these compounds and processes for preparing them
ZA931332B (en) Pharmaceutical compounds
GB9218112D0 (en) Pharmaceutical compounds
GB9209028D0 (en) Pharmaceutical compounds
GB9213058D0 (en) Pharmaceutical compounds
GB9218090D0 (en) Pharmaceutical compounds